Skip to content
Screener

Krystal Biotech, Inc. KRYS Q3 2025 earnings

Reported November 3, 2025 · Before market open

Revenue$97.8MMiss by $7.5M
EPS$2.66Beat by $1.54
Revenue estimate$105.3M
EPS estimate$1.12

Next report

Nov 2, 2026 (in a month)
Revenue estimate$129.1M
EPS estimate$1.91

Financials

Q3 2025

Income statement

See full
Revenue$97.8M+16.6%
Operating income$41.4M+84.1%
Net income$79.4M+192%
EPS (diluted)$2.66+192%

Balance sheet

See full
Cash & equivalents$392.6M+5.0%
Total debt$9.5M+27.2%
Total equity$1.1B+28.5%
Total assets$1.2B+26.2%

Cash flow

See full
Operating cash flow$39.7M-32.6%
CapEx$1.7M+62.9%
Free cash flow$38.0M-34.3%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$5.11B-1.9%
Enterprise value$4.73B-2.3%
P/E25.7×-73.7×
P/S13.7×-7.9×

Profitability

See full
Operating margin42.4%+32.3pp
Net margin53.3%+31.6pp
FCF margin44.4%+18.1pp

Returns & leverage

See full
Return on equity19.7%+13.3pp
Debt / equity0×0.0×
Current ratio10.1×+2.2×

FAQ

When did Krystal Biotech, Inc. report Q3 2025 earnings?
Krystal Biotech, Inc. (KRYS) reported Q3 2025 earnings on November 3, 2025 before market open.
What were Krystal Biotech, Inc.'s Q3 2025 revenue and EPS?
Krystal Biotech, Inc. reported revenue of $97.8M and eps of $2.66 for Q3 2025.
Did Krystal Biotech, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $105.3M by $7.5M. EPS beat the consensus estimate of $1.12 by $1.54.
How did Krystal Biotech, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.6% from $83.8M a year earlier and eps grew 192.3% from $0.91.
Where can I find Krystal Biotech, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001711279-25-000088) and the 10-Q periodic report (0001711279-25-000087) directly on SEC EDGAR. The filing index links above go to sec.gov.